Pharsight

Eysuvis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11596599 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

Eysuvis is owned by Alcon Labs Inc.

Eysuvis contains Loteprednol Etabonate.

Eysuvis has a total of 2 drug patents out of which 0 drug patents have expired.

Eysuvis was authorised for market use on 26 October, 2020.

Eysuvis is available in suspension/drops;ophthalmic dosage forms.

Eysuvis can be used as a method for treating dry eye in a patient.

The generics of Eysuvis are possible to be released after 03 May, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219596 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10857096 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10945948 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10940108 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10993908 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10646436 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

Eysuvis is owned by Kala Pharms Inc.

Eysuvis contains Loteprednol Etabonate.

Eysuvis has a total of 13 drug patents out of which 0 drug patents have expired.

Eysuvis was authorised for market use on 26 October, 2020.

Eysuvis is available in suspension/drops;ophthalmic dosage forms.

Eysuvis can be used as a method for treating dry eye in a patient, administration to the eye of a patient for treatment of dry eye condition, a method for delivering a composition to a mucus membrane, a method for delivering a pharmaceutical agent across a mucosal barrier.

The generics of Eysuvis are possible to be released after 03 May, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic